People with autoimmune skin diseases had significantly better cancer survival outcomes than others. Survival benefits were ...

Many people with psoriasis change medications at some point during treatment. So, whether your old medication isn’t working as well or you’re having too many side effects, here’s how to make ...

“While the phase 3 results of GCAptAIN did not replicate the positive outcomes observed in the phase 2 trial, we remain committed to continuing to drive scientific progress and deepening the ...

Novartis' blockbuster immunology drug Cosentyx has disappointed in a phase 3 trial involving patients with giant cell ...

ORLANDO, FLORIDA / ACCESS Newswire / July 3, 2025 / RedChip Companies will air interviews with Fathom Holdings, Inc.

Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial ...

Patients with autoimmune skin diseases had improved survival after cancer treatment, suggesting a potential immunologic advantage and prompting further research into autoimmune-cancer interactions.

The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1 ...

AbbVie has announced that it will be expanding its immunology capabilities by acquiring Capstan Therapeutics for up to $2.1bn ...

Medically reviewed by Casey Gallagher, MD Eyebrow dandruff occurs when dead skin cells shed faster than usual. It causes white, yellow, or gray flakes around your brows. Seborrheic dermatitis, a skin ...

Novartis NVS announced that a late-stage study of its interleukin-17A inhibitor, Cosentyx (secukinumab), has failed to meet ...

That’s where anti-inflammatory therapeutics come into play, offering hope for millions of people living with chronic inflammation. The global anti-inflammatory therapeutics market size was $98,026 ...